Published in:
01-08-2013 | Letter
Concerns about renal safety of HES 130
Authors:
Christian J Wiedermann, Michael Joannidis
Published in:
Critical Care
|
Issue 4/2013
Login to get access
Excerpt
In a meta-analysis of 34 randomized trials evaluating hydroxyethyl starch (HES) 130/0.4 in 9,587 patients and a meta-analysis evaluating HES 130/0.42 in 804 patients, HES 130 was shown to increase mortality and the need for renal replacement therapy (RRT) [
1]. In the largest included trial of the meta-analysis, the Crystalloid versus Hydroxyethyl Starch Trial (CHEST) with 7,000 ICU patients [
2], HES 130/0.4 increased the need for RRT despite a low average daily dose of only 526 ml. The meta-analysis also included RRT data from the CRYSTMAS trial that had not been reported in the original publication of that trial but were later published in a letter to
Critical Care [
3] and also incorporated in revised US Prescribing Information for HES 130/0.4 [
4]. …